Compare Crispr Therapeutics AG (CRSP) vs Freeport-McMoRan Inc (FCX) Price & Performance

CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.

Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.